26.01.2025, 2639 Zeichen

Marinomed: Marinomed Biotech AG announced that the restructuring proceedings without self-administration opened on August 14^th, 2024, have been formally completed by resolution of the Korneuburg regional court on January 14^th, 2025. In December, the Company met all necessary prerequisites, including depositing the funds required for payment of the cash quota and the costs of the proceedings. With the formal end of the proceedings, administration by the insolvency administrator has also ended and the Management Board has regained control over the Company. “We are relieved that we were able to successfully complete the restructuring process. With the sale of the Carragelose business, we are well positioned to fulfill the restructuring plan. At the same time, our top priorities are now to develop a new strategy and to push ahead with the commercialization of our Marinosolv and Solv4U assets”, saya Andreas Grassauer, CEO of Marinomed.
Marinomed Biotech: weekly performance: -2.04%

Valneva: Austrian/French Valneva, a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ^®, which showed a sustained 98.3% sero-response rate one-year after single vaccination. These results support and strengthen the pivotal data previously reported for adolescents (12 to 17 years old) which supported filing for potential label extension to this age group in the U.S., Europe, and Canada. Data from this trial are also expected to support licensure of IXCHIQ^® in Brazil, which would be the first potential approval for use in endemic populations.
Valneva: weekly performance: 9.65%

RBI: In the legal proceedings initiated by Rasperia Trading Limited against STRABAG SE, STRABAG SE’s Austrian core shareholders and RBI’s (Raiffeisen Bank International) wholly owned Russian subsidiary AO Raiffeisenbank, a Russian court has rendered its verdict. The court has decided that STRABAG SE and its Austrian core shareholders are liable to pay EUR 2.044 billion to Rasperia and that the verdict can be enforced against AO Raiffeisenbank’s assets. AO Raiffeisenbank will appeal this verdict with suspensive effect. Subject to further developments in Russian courts, RBI Group will take legal actions in Austria, in full compliance with EU sanction law, to mitigate damages by seeking enforcement against Rasperia’s assets in Austria. AO Raiffeisenbank will book a provision for Q4/2024, in accordance with IFRS and Russian accounting standards.
RBI: weekly performance: 1.73%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (20/01/2025)

Christian Drastil: Wiener Börse Plausch

Private Investor Relations Podcast #12: Ina Sabitzer moderiert die CIRA-Jahreskonferenz 2026 zum 10. Mal, im Podcast gibts Key Take aways

Bildnachweis

Aktien auf dem Radar:VIG, FACC, RBI, Pierer Mobility, Austriacard Holdings AG, Rosenbauer, DO&CO, Palfinger, Warimpex, Kapsch TrafficCom, Frequentis, Gurktaler AG Stamm, Oberbank AG Stamm, Amag, Flughafen Wien, Österreichische Post, Strabag, Telekom Austria, GEA Group, Siemens, HeidelbergCement, MTU Aero Engines, Fresenius Medical Care, Deutsche Bank, Deutsche Post, BMW, Porsche Automobil Holding, Continental, Vonovia SE, Bayer, Rheinmetall.

---